These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 12869391)

  • 21. The protective effect of trimetazidine on myocardial ischemia/reperfusion injury through activating AMPK and ERK signaling pathway.
    Liu Z; Chen JM; Huang H; Kuznicki M; Zheng S; Sun W; Quan N; Wang L; Yang H; Guo HM; Li J; Zhuang J; Zhu P
    Metabolism; 2016 Mar; 65(3):122-30. PubMed ID: 26892523
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chronic angina: new medical options for treatment.
    McCullough PA
    Rev Cardiovasc Med; 2005; 6(3):152-61. PubMed ID: 16195688
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ranolazine. A metabolic modulator for the treatment of chronic stable angina.
    Anderson JR; Nawarskas JJ
    Cardiol Rev; 2005; 13(4):202-10. PubMed ID: 15949056
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metabolic energy metabolism in diabetes: therapeutic implications.
    Pogatsa G
    Coron Artery Dis; 2001 Feb; 12 Suppl 1():S29-33. PubMed ID: 11286305
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 4-bromotiglic acid, a novel inhibitor of thiolases and a tool for assessing the cooperation between the membrane-bound and soluble beta-oxidation systems of rat liver mitochondria.
    Liang X; Schulz H
    Biochemistry; 1998 Nov; 37(44):15548-54. PubMed ID: 9799519
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Trimetazidine and cardioprotection during ischemia-reperfusion].
    Barsotti A; Di Napoli P
    Ital Heart J; 2004 Mar; 5 Suppl 2():29S-36S. PubMed ID: 15074775
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure.
    Rupp H; Zarain-Herzberg A; Maisch B
    Herz; 2002 Nov; 27(7):621-36. PubMed ID: 12439634
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of trimetazidine on carnitine palmitoyltransferase-1 in the rat heart.
    Kennedy JA; Horowitz JD
    Cardiovasc Drugs Ther; 1998 Sep; 12(4):359-63. PubMed ID: 9825181
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Efficiency of trimetazidine treatment of experimental ischemic heart disease in age aspect].
    Kukes VG; Zhernakova NI; Gorbach TV; Romashchenko OV; Rumbesht VV
    Eksp Klin Farmakol; 2013; 76(2):9-12. PubMed ID: 23631276
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiac mitochondrial alterations induced by insulin deficiency and hyperinsulinaemia in rats: targeting membrane homeostasis with trimetazidine.
    Ovide-Bordeaux S; Bescond-Jacquet A; Grynberg A
    Clin Exp Pharmacol Physiol; 2005 Dec; 32(12):1061-70. PubMed ID: 16445572
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Treating ischemic heart disease by pharmacologically improving cardiac energy metabolism].
    Lopaschuk GD
    Presse Med; 1998 Dec; 27(39):2100-4. PubMed ID: 9893703
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ranolazine inhibits an oxidative stress-induced increase in myocyte sodium and calcium loading during simulated-demand ischemia.
    Zhang XQ; Yamada S; Barry WH
    J Cardiovasc Pharmacol; 2008 May; 51(5):443-9. PubMed ID: 18398379
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ranolazine as a cardioplegia additive improves recovery of diastolic function in isolated rat hearts.
    Hwang H; Arcidi JM; Hale SL; Simkhovich BZ; Belardinelli L; Dhalla AK; Shryock JC; Kloner RA
    Circulation; 2009 Sep; 120(11 Suppl):S16-21. PubMed ID: 19752362
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression and purification of His-tagged rat mitochondrial 3-ketoacyl-CoA thiolase wild-type and His352 mutant proteins.
    Zeng J; Li D
    Protein Expr Purif; 2004 Jun; 35(2):320-6. PubMed ID: 15135409
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trimetazidine-induced enhancement of myocardial glucose utilization in normal and ischemic myocardial tissue: an evaluation by positron emission tomography.
    Mody FV; Singh BN; Mohiuddin IH; Coyle KB; Buxton DB; Hansen HW; Sumida R; Schelbert HR
    Am J Cardiol; 1998 Sep; 82(5A):42K-49K. PubMed ID: 9737485
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trimetazidine in the myocardial cell mechanisms of cytoprotection.
    Labrid C
    Rom J Intern Med; 1998; 36(3-4):137-44. PubMed ID: 10822510
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of L-carnitine on mitochondrial acyl CoA esters in the ischemic dog heart.
    Kobayashi A; Fujisawa S
    J Mol Cell Cardiol; 1994 Apr; 26(4):499-508. PubMed ID: 8072006
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of metabolically active drugs in the management of ischemic heart disease.
    Schofield RS; Hill JA
    Am J Cardiovasc Drugs; 2001; 1(1):23-35. PubMed ID: 14728049
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabolic manipulation in ischaemic heart disease, a novel approach to treatment.
    Lee L; Horowitz J; Frenneaux M
    Eur Heart J; 2004 Apr; 25(8):634-41. PubMed ID: 15084367
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolic therapy in the treatment of ischaemic heart disease: the pharmacology of trimetazidine.
    Stanley WC; Marzilli M
    Fundam Clin Pharmacol; 2003 Apr; 17(2):133-45. PubMed ID: 12667223
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.